Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations (In thousands, except per share amounts)Three months endedNine months endedSeptember 30,September 30,2011201020112010(unaudited)(unaudited)RevenuesManufacturing services

$  1,713$  1,846$  4,390$  5,258Collaborative agreements

1,7465,7836,2537,343  Total revenues

3,4597,62910,64312,601Operating ExpensesCost of manufacturing services

1,5571,8146,2155,309Research and development

14,97820,15545,61658,971General and administrative

6,0296,86218,99620,636Restructuring charges

003,4670Amortization of acquired technology & other intangibles

1975418191,609  Total operating expenses

22,76129,37275,11386,525Interest and Other Income (Expense)Interest income

20107102338Interest expense

(3,211)(6,267)(11,087)(16,198)Gain (Loss) from valuation of derivative liabilities

(233)3,0233874,857Loss on extinguishment of debt

0(12,354)(10,514)(12,354)Other

(10)96840988  Total interest and other expense, net

(3,434)(14,523)(21,072)(22,369)Net loss

(22,736)(36,266)(85,542)(96,293)Deemed dividend related to beneficial conversion feature of convertible preferred stock

00(2,260)0Net loss allocable to common stockholders

$(22,736)$(36,266)$(87,802)$(96,293)Net loss per share allocable to common stockholders, basic

$(0.16)$(0.31)$(0.64)$(0.91)Net loss per share allocable to common stockholders, diluted

$(0.16)$(0.31)$(0.64)$(0.91)Shares used in calculating net loss per share allocable to common stockholders, basic

145,965117,409136,860105,582Shares used in calculating net loss per share allocable to common stockholders, diluted

145,965117,409136,860105,582Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)September 30, 2011December 31, 2010(unaudited)(1)Assets  Cash and cash equivalents

$ 77,8
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --   Millstone Medical Outsourcing announced today that the company ... Olive Branch, MS. Now totaling over 270,000 square ... added the capacity required to meet the high demand of ... us the opportunity to grow in parallel with our customers," ... and a half years ago we were operating only 46,000 ...
(Date:9/1/2015)...   Ivenix Inc. , a medical technology ... on a $42M round of equity financing led ... CICA, Inc., Easterly Capital, Fidelity Biosciences, and SCP ... financing will support the company,s efforts to enter ... acted as the exclusive placement agent for the ...
(Date:9/1/2015)... -- In nur zwei Jahren nach dem Erreichen ... Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese Steigerung ... Markt der injizierbaren Medikamente und das ... SHL wieder. Foto - http://photos.prnewswire.com/prnh/20150820/259886 ... Design und Herstellung automatischer Injektoren und Pen-Injektoren und ...
Breaking Medicine Technology:Millstone Medical Outsourcing Announces Olive Branch Expansion 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
... Health Company (FHCO- NASDAQ-CM) today announced that its exclusive distributor ... (PTY) Ltd., has received an order from the RSA Department ... for delivery as soon as possible. Shipments against the order ... Parrish, Chairman and C.E.O. of The Female Health Company, noted ...
Cached Medicine Technology:Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 2The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY) Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South Africa Department of Health 3
(Date:9/1/2015)... ... 01, 2015 , ... According to a study published August 25th ... participated in a three year study about weight loss and diabetes were far more ... weight loss surgery at the onset of the trial. In fact, the participants in ...
(Date:9/1/2015)... ... 01, 2015 , ... Stress comes in many different forms ... changes can lead to very serious, life-altering events. Fortunately nature offers a range ... supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. ... issues and needs. Money for Good 2015, released today by Camber Collective, goes to ... annual potential to mobilize up to $22B in new philanthropic giving and shift $25B ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... therapeutic options to efficiently cure and prevent different malignancies. Some options for ... different pathophysiological properties due to which distinctive approach is necessary for effective ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and IT ... the escalating renewal prices and inadequate customer services of existing remote support solution, ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... March 15, 2011Since the first laparoscopic procedure was performed ... Washington University in St. Louis, this breakthrough minimally invasive ... nephrectomy. This remarkable achievement is celebrated with a series ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ...
... are not successfully treated for depression are at higher risk ... to a study in the March 15, 2011 issue of ... as a third of those who experience a stroke develop ... the schools of health and rehabilitation sciences and of medicine ...
... Institutet in Sweden shows, that a specific inflammatory factor ... valve disease aortic stenosis. The results suggest that anti-inflammatory ... stenosis is the most common heart valve disease, which ... the aortic valve. This is typically seen in the ...
... (BCS) results from hepatic venous outflow obstruction,at any ... Few patients respond to,medical treatment (anticoagulation thrombolytic ... restore the hepatic blood flow. Restoring outflow in ... dilatation stenting is the management of choice. ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... for type 2 diabetes, an older drug -- metformin -- ... analysis of research on diabetes medications. The analysis ... all of them lower blood sugar levels by a similar ...
... home industry is booming in China as a rapid ... a nationwide shift from traditional family care to institutional ... The study, led by Zhanlian Feng, assistant professor ... Journal of the American Geriatrics Society , is the ...
Cached Medicine News:Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3Health News:Inflammation behind heart valve disease 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: